Other Stories

COVID-19 treatment made by S. Korea's Celltrion under review Updated: 2020-12-30 05:38:43 KST

The antibody treatment for COVID-19 made by a South Korean pharmaceutical giant, Celltrion has gone under review.
According to the Ministry of Food and Drug Safety, a COVID-19 vaccine and treatment licensing review team aims to finish the review and to grant approval within 40 days.
This comes as the company applied for the ministry's permission on Tuesday.
Celltrion is the third company in the world to apply for approval for an experimental COVID-19 treatment.
The company has also applied for emergency-use approval in the U.S. and Europe.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.